• Mashup Score: 1

    Toutes les questions marquées d’une (*) sont obligatoires Vous êtes* Une femme Un homme Age* Votre spécialité* Cardiologie générale Rythmologie Cardiologie interventionnelle Insuffisance cardiaque Autre Votre durée d’exercice* < 10 ans...

    Tweet Tweets with this article
    • RT @SABOURETCardio: Enquête nationale National survey about #PCSK9i use (French version) #poll #Cardiotwitter https://t.co/kmHxbUlV52

  • Mashup Score: 5

    Preclinical evidence suggests that proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors hold anti-inflammatory properties independently of their ability to lower LDL-cholesterol (C). However, whether PCSK9 inhibitors exert anti-inflammatory effects within the atherosclerotic plaque in humans is unknown. We explored the impact of PCSK9 inhibitors, used as monotherapy, compared with other lipid-lowering drugs (oLLD) on the expression of inflammatory markers within the plaque, assessing also the subsequent incidence of cardiovascular events.

    Tweet Tweets with this article
    • RT @SABOURETCardio: Evidence of an anti-inflammatory effect of #PCSK9i within the human atherosclerotic #plaque - https://t.co/CV4cOKZlM0

  • Mashup Score: 6

    Preclinical evidence suggests that proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors hold anti-inflammatory properties independently of their ability to lower LDL-cholesterol (C). However, whether PCSK9 inhibitors exert anti-inflammatory effects within the atherosclerotic plaque in humans is unknown. We explored the impact of PCSK9 inhibitors, used as monotherapy, compared with other lipid-lowering drugs (oLLD) on the expression of inflammatory markers within the plaque, assessing also the subsequent incidence of cardiovascular events.

    Tweet Tweets with this article
    • Evidence of an anti-inflammatory effect of #PCSK9i within the human atherosclerotic #plaque - https://t.co/CV4cOKZlM0